Phase 2 Peripheral Neuropathy Trial, Recruiting NCT04789044 Sponsor: Major Extremity Trauma Research Consortium Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT04789044
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 80 years old
  • People who have had a complete peripheral nerve injury in the arm caused by trauma, and who arrive for treatment within 48 hours of the injury
  • People whose injury affects movement and/or feeling in one of these specific arm nerves: the axillary, radial, median, ulnar, or musculocutaneous nerve, and where the injury is located between the upper arm bone (humerus) and the wrist crease
  • People whose injured nerve, at the location of the injury, would normally carry both movement and sensation signals (confirm with trial site)

Who may not be able to join:

  • People who need surgery within just a few hours of the injury, before trial processes can begin
  • People whose nerve injury involves the brachial plexus (the network of nerves closer to the neck and shoulder)
  • People whose nerve injury is below the wrist crease
  • People whose injury only involves a nerve branch that carries sensation only, or certain specific nerve branches in the forearm beyond their midpoint (confirm with trial site for specific nerve names)
  • People who have had a previous peripheral nerve injury, or who have a history of stroke, or a muscle, nerve, or neuromuscular condition
  • People who have a documented psychiatric condition that is considered likely to result in self-harm or make it difficult to attend follow-up appointments
  • People who are likely to have serious difficulties attending follow-up visits, such as those who are in prison or experiencing homelessness at the time of injury, or those with intellectual challenges without adequate family support
  • People who are not expected to survive the next 30 days due to their injuries or health condition
  • People who have a known allergy to polyethylene glycol (PEG)
  • People where certain baseline assessments cannot be completed on the uninjured arm, or where sensation testing on the uninjured arm shows results above a specific threshold during the baseline assessment (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People who have a significant other health condition that would prevent immediate surgical repair of the nerve
  • People who are unable to closely follow all requirements of the clinical trial protocol

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ala Elhelali, PhD, Johns Hopkins University

Phone: 410-955-0396

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Major Extremity Trauma Research Consortium
Registry
ClinicalTrials.gov
Start date
1 June 2023
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Complications or problems that occur with in the first 30 days.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov